Duloxetine HCL DR Capsules SPE2D2-25-R-0010
Summary
AI-generated · Aug 23, 2025Duloxetine HCL delayed-release capsules are being procured under SPE2D2-25-R-0010 through a combined synopsis/solicitation. The excerpt identifies only the product and solicitation number; it does not provide quantities, dosage strengths, packaging, delivery schedule, or any technical, regulatory, or submission requirements.
Records 2–5 repeat the same solicitation reference with no additional details or changes noted. No brand-name, certification, or site-visit requirements are indicated in these excerpts; the full solicitation should be consulted for complete requirements and any addenda.
SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation
From Combined Synopsis/Solicitation posted on Jun 17, 2025SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation
From Combined Synopsis/Solicitation posted on Jul 17, 2025SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation
From Combined Synopsis/Solicitation posted on Jul 30, 2025SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation
From Combined Synopsis/Solicitation posted on Aug 14, 2025SPE2D2-25-R-0010 Duloxetine HCL DR Solicitation
From Combined Synopsis/Solicitation posted on Aug 21, 2025Notice history
5-
Combined Synopsis/Solicitation Posted Jun 17, 2025
-
Combined Synopsis/Solicitation Posted Jul 17, 2025View changes (1)
- Response Deadline: Jun 18, 2025 → Aug 01, 2025
-
Combined Synopsis/Solicitation Posted Jul 30, 2025View changes (1)
- Response Deadline: Aug 01, 2025 → Aug 15, 2025
-
Combined Synopsis/Solicitation Posted Aug 14, 2025View changes (1)
- Response Deadline: Aug 15, 2025 → Aug 22, 2025
-
Combined Synopsis/Solicitation LATEST Posted Aug 21, 2025View changes (1)
- Response Deadline: Aug 22, 2025 → Sep 05, 2025
Details
Award Information
Not yet awarded
Contacts
Phone
Phone